- Home
- HOOD vs ARGX Comparison
HOOD vs ARGX Comparison
Compare HOOD & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOD
- ARGX
- Stock Information
- Founded
- HOOD 2013
- ARGX 2008
- Country
- HOOD United States
- ARGX Netherlands
- Employees
- HOOD N/A
- ARGX N/A
- Industry
- HOOD Computer Software: Prepackaged Software
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HOOD Technology
- ARGX Health Care
- Exchange
- HOOD Nasdaq
- ARGX Nasdaq
- Market Cap
- HOOD 35.5B
- ARGX 40.4B
- IPO Year
- HOOD 2021
- ARGX 2017
- Fundamental
- Price
- HOOD $51.60
- ARGX $644.48
- Analyst Decision
- HOOD Buy
- ARGX Strong Buy
- Analyst Count
- HOOD 17
- ARGX 20
- Target Price
- HOOD $61.40
- ARGX $653.11
- AVG Volume (30 Days)
- HOOD 28.1M
- ARGX 225.0K
- Earning Date
- HOOD 02-12-2025
- ARGX 02-27-2025
- Dividend Yield
- HOOD N/A
- ARGX N/A
- EPS Growth
- HOOD N/A
- ARGX N/A
- EPS
- HOOD 1.56
- ARGX N/A
- Revenue
- HOOD $2,951,000,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- HOOD $27.45
- ARGX $73.18
- Revenue Next Year
- HOOD $12.84
- ARGX $55.26
- P/E Ratio
- HOOD $33.08
- ARGX N/A
- Revenue Growth
- HOOD 58.23
- ARGX 85.56
- 52 Week Low
- HOOD $13.98
- ARGX $349.86
- 52 Week High
- HOOD $66.91
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- HOOD 48.01
- ARGX 49.33
- Support Level
- HOOD $52.65
- ARGX $637.15
- Resistance Level
- HOOD $66.91
- ARGX $652.23
- Average True Range (ATR)
- HOOD 3.68
- ARGX 12.63
- MACD
- HOOD -0.61
- ARGX -1.94
- Stochastic Oscillator
- HOOD 18.69
- ARGX 30.64
About HOOD Robinhood Markets Inc.
Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fractional shares, recurring investments, and IPO Access. It earns transaction-based revenues from routing user orders for options, equities, and cryptocurrencies to market makers when a routed order is executed.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.